Due to the selective inhibition of FGFC1 on H1975 erlotinib-resistant NSCLC cells and its inhibition on the phosphorylation of Akt, we tested the activation of EGFR and its downstream signaling pathway PI3K/Akt/mTOR after FGFC1 treatment (Jorissen et al., 2003; Seshacharyulu et al., 2012). The gene discussed is MTOR; the disease is non-small cell lung carcinoma.